Drug intelligence / Profile preview

pirnabine

Development stage: Unknown
Lead developer: Aquestive Therapeutics
Modality: Small Molecules
Administration: Ophthalmic, Oral

Overview

Pirnabine is a synthetic small molecule drug classified as a cannabinoid receptor ligand. It was originally developed for the treatment of glaucoma and has also been investigated in clinical trials for chronic idiopathic constipation. Pirnabine is structurally related to dibenzopyran compounds and may exert its effects by binding to cannabinoid receptors involved in gastrointestinal motility regulation, although its precise mechanism of action remains under investigation. The compound's IUPAC name is 3,6,6,9-tetramethyl-6H,7H,8H,9H,10H-cyclohexa[c]chromen-1-yl acetate.

Other names: pirnabinguanlib

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on pirnabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pirnabine.

Explore the full profile